Zobrazeno 1 - 10
of 2 049
pro vyhledávání: '"Farhad Ravandi"'
Autor:
Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Farhad Ravandi
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-24 (2024)
Abstract The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeutic targets and the development of corresponding novel targeted therapies. Since 2017, twelve agents have been approved
Externí odkaz:
https://doaj.org/article/3a838f9aa5f045b186539449d87c7e7e
Autor:
Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi Haddad, Tharakeswara Bathala, Iuliia Kovalenko, Aram Bidikian, Farhad Ravandi, Issa Khouri, Tapan M. Kadia, Rebecca Garris, Guillermo Montalban Bravo, Kelly Chien, Elizabeth Shpall, Partow Kebriaei, Hagop M. Kantarjian
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/cb51845e37254d6d8ab98fdbb4b106f4
Autor:
Alex Bataller, Hagop Kantarjian, Alexandre Bazinet, Tapan Kadia, Naval Daver, Courtney D. DiNardo, Gautam Borthakur, Sanam Loghavi, Keyur Patel, Guilin Tang, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Ghayas C. Issa, Yesid Alvarado, Guillermo Montalban-Bravo, Abhishek Maiti, Hussein A. Abbas, Koichi Takahashi, Sherry Pierce, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Patients with relapsed acute myeloid leukemia (rAML) experience dismal outcomes. We performed a comprehensive analysis of patients with rAML to determine the genetic dynamics and survival predictive factors. We analyzed 875 patients with newly diagno
Externí odkaz:
https://doaj.org/article/933107ee2d9a47c0ad4b8d730636ebc4
Autor:
Agata Gruszczynska, Abhishek Maiti, Christopher A. Miller, Sai Mukund Ramakrishnan, Daniel C. Link, Geoffrey L. Uy, Allegra A. Petti, Kala Hayes, Courtney D. DiNardo, Farhad Ravandi, Timothy J. Ley, David H. Spencer, Feng Gao, Marina Y. Konopleva, John S. Welch
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/68bab4a8237f41da908adeab2a2bab9b
Autor:
Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, Courtney D. DiNardo
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/b7c6599d1ff945fc8f42960c8b15f42e
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3 internal tandem duplication (ITD) mutations being associated with a more aggressive clinical course. While two large, randomized clinical trials have shown a
Externí odkaz:
https://doaj.org/article/94d666d3cbf74ef1b58c801b73960961
Autor:
Nicholas J. Short, Muharrem Muftuoglu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban-Bravo, Yesid Alvarado, Mahesh Basyal, Naval Daver, Courtney D. Dinardo, Gautam Borthakur, Nitin Jain, Maro Ohanian, Elias Jabbour, Ghayas C. Issa, Wei Qiao, Xuelin Huang, Rashmi Kanagal-Shamanna, Keyur P. Patel, Prithviraj Bose, Farhad Ravandi, Ricardo Delumpa, Regina Abramova, Guillermo Garcia-Manero, Michael Andreeff, Jorge Cortes, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-11 (2023)
Abstract Background Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedista
Externí odkaz:
https://doaj.org/article/ad7ca09609614d58a1b068a42eba3a40
Autor:
Jayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, Hussein A. Abbas, Sanam Loghavi, Gautam Borthakur, Musa Yilmaz, Ghayas C. Issa, Samuel I. Dara, Mahesh Basyal, Li Li, Kiran Naqvi, Rasoul Pourebrahim, Elias J. Jabbour, Steven M. Kornblau, Nicholas J. Short, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Joseph Khoury, Naval Daver, Hagop M. Kantarjian, Michael Andreeff, Courtney D. DiNardo
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-6 (2023)
Abstract In TP53 wild-type acute myeloid leukemia (AML), inhibition of MDM2 can enhance p53 protein expression and potentiate leukemic cell apoptosis. MDM2 inhibitor (MDM2i) monotherapy in AML has shown modest responses in clinical trials but combini
Externí odkaz:
https://doaj.org/article/e09e6500217f443ab08d9d78cb583310
Autor:
Hagop Kantarjian, Fadi G. Haddad, Nitin Jain, Koji Sasaki, Nicholas J. Short, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Yesid Alvarado, Tapan Kadia, Shilpa Paul, Guillermo Garcia-Manero, Bouthaina Dabaja, Musa Yilmaz, Jovitta Jacob, Rebecca Garris, Susan O’Brien, Farhad Ravandi, Elias Jabbour
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-12 (2023)
Abstract Background Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential blinatumomab to low-in
Externí odkaz:
https://doaj.org/article/b4f44ab39b2049e6b4e01db67dec5fb5
Autor:
Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Mary Alma Welch, Farhad Ravandi, Hagop Kantarjian
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-19 (2023)
Abstract Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is accelerating. This analysis summarizes the data derived from the clinical trials conducted at MD Anderson between 1985 and 2022 across ALL subtypes. In Phila
Externí odkaz:
https://doaj.org/article/aaa54c0f0e1b4c3e963d0865c524d563